GLP-1 Agonists Linked to Anorgasmia in a 71-Year-Old Woman
Clinicians prescribing GLP-1 agents should ask about sexual function and consider medication review if new anorgasmia appears. Medscape UK
Tesla $1T pay OK; AI chip plans lift Intel | ITV soars; Novo dips; Oracle funds AI
Big cap moves across AI, media, and biotech today. Tesla’s $1T Musk package gets the nod as the company eyes an AI chip factory with a potential Intel tie-up. ITV jumps on a £1.6B sale talk; Novo trims U.S. GLP-1 prices and slips. Image: Today’s market snapshot Core facts: – Tesla (TSLA): Shareholders approved Musk’s […]
GLP-1 drugs beat metformin for weight control in teens with type 2 diabetes
In youth newly diagnosed with type 2 diabetes, GLP-1–based therapies, including semaglutide and tirzepatide, achieved similar blood sugar control but significantly greater reductions in body mass index than metformin. These findings highlight the potential of high-potency GLP-1 agents as effective monotherapy options in managing obesity and glycemic control in adolescents.
Mark Cuban strongly reacts to major Medicare change
Originally a trade term, Most-Favored-Nation status aims to ensure equal treatment among trading partners. In medication pricing, its goal is that the U.S. will get the best deal available globally. Specifically, MFN prescription drug pricing ties cost in the U.S. to the lowest price paid by other wealthy nations — such as Canada, Germany, or […]
GLP-1 shoppers find answers in the dairy section: report
Dairy Trends Report shows people taking weight-loss drugs consume yogurt nearly three times the average
Eli Lilly cuts surprising deals with upstart biotech players
Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the pharmaceutical giant announced two strategic deals, following the highly anticipated deal with the White House. The move underlines Eli Lilly’s ambition to expand beyond its dominant obesity and diabetes franchises and enter cutting-edge […]
Semaglutide’s MASH Benefits Extend Beyond Weight Loss
(MedPage Today) — WASHINGTON — Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) through both weight loss-related and direct biological effects, according…
More of Its Money and a Little Help from Washington: How Pfizer Won Metsera
Pfizer has won the week-long bidding war for Metsera with an upwardly revised up-to-$10 billion offer matching that of rival Novo Nordisk—and more than a little help from Washington. Novo Nordisk has given up on trying to outbid Pfizer to acquire the obesity and metabolic drug developer after one-upping the pharma giant last week. Metsera […]
As Access to Weight Loss Medication Expands, Foodsmart’s ‘GLP-1 Companion Care’ Program Delivers Proven Medical and Pharmacy Savings through Integrated Nutrition and Lifestyle Management
SAN FRANCISCO, Nov. 10, 2025 /PRNewswire/ — Foodsmart, the leading telenutrition and foodcare provider nationwide, is expanding access to its GLP-1 Companion Care program after validating savings of $2,000 per GLP-1 patient annually versus those using medication alone. With the CMS…
Will Lower GLP-1 Prices Undermine Novo Nordisk’s Near-Term Outlook?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, which markets its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and Wegovy (for obesity). Following President Trump’s comments last month on forthcoming government action to reduce the prices of Ozempic and Wegovy, Novo Nordisk disclosed last week that it has reached […]